Sage Therapeutics, Inc. News Releases https://investor.sagerx.com/ Sage Therapeutics, Inc. News Releases en Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-present-2019-rbc-capital-markets-global CAMBRIDGE, Mass --(BUSINESS WIRE)--May 14, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare Tue, 14 May 2019 06:30:00 -0400 Sage Therapeutics, Inc. News Releases 10246 Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-present-bank-america-merrill-lynch-2019-health CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Tue, 07 May 2019 16:01:00 -0400 Sage Therapeutics, Inc. News Releases 10226 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-inducement-grants-under-nasdaq-23 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019 , the Compensation Committee of Sage’s Board of Mon, 06 May 2019 16:45:00 -0400 Sage Therapeutics, Inc. News Releases 10216 Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-first-quarter-2019-financial-results ZULRESSO™ (brexanolone) injection approved by U.S. FDA and on track for launch in late June Commercial team is launch ready; field teams focusing on payer engagement and identifying pathways to care Strong financial position with ~$1.4B in cash Milestones anticipated throughout 2019 in clinical Thu, 02 May 2019 06:30:00 -0400 Sage Therapeutics, Inc. News Releases 10191 Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019 https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-report-first-quarter-2019-financial-results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thu, 18 Apr 2019 16:30:00 -0400 Sage Therapeutics, Inc. News Releases 10161 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-inducement-grants-under-nasdaq-22 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 1, 2019 , the Compensation Committee of Sage’s Wed, 03 Apr 2019 06:30:00 -0400 Sage Therapeutics, Inc. News Releases 10156 Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-fda-approval-zulressotm-brexanolone Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms within days Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in Tue, 19 Mar 2019 19:00:00 -0400 Sage Therapeutics, Inc. News Releases 10131 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-inducement-grants-under-nasdaq-21 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2019 , the Compensation Committee of Sage’s Tue, 05 Mar 2019 06:30:00 -0500 Sage Therapeutics, Inc. News Releases 10116 Sage Therapeutics Announces Closing of $575 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-closing-575-million-public-offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2019-- Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public Wed, 27 Feb 2019 16:01:00 -0500 Sage Therapeutics, Inc. News Releases 10096 Sage Therapeutics Prices Public Offering of Common Stock https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-prices-public-offering-common-stock-1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 Mon, 25 Feb 2019 21:05:00 -0500 Sage Therapeutics, Inc. News Releases 10081